Data gathered: January 2
AI Stock Analysis - RedHill Biopharma (RDHL)
Analysis generated August 9, 2024. Powered by Chat GPT.
RedHill Biopharma, a specialty biopharmaceutical company, focuses on the development and commercialization of drugs for gastrointestinal diseases and infectious diseases. Based in Israel, the company combines a robust pipeline with a commercial-stage platform, aiming to innovate in areas of high unmet medical needs. The company's core products include Talicia for the treatment of H. pylori infection, Movantik for opioid-induced constipation, and RHB-204 for NTM infections, among others.
Stock Alerts - RedHill Biopharma (RDHL)
 |
RedHill Biopharma | January 2 Price is up by 7.4% in the last 24h. |
|
RedHill Biopharma | December 31 Price is down by -5.1% in the last 24h. |
|
RedHill Biopharma | December 27 Price is up by 5.3% in the last 24h. |
|
RedHill Biopharma | December 26 Price is up by 5% in the last 24h. |
Alternative Data for RedHill Biopharma
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 90 | Sign up | Sign up | Sign up |
| Webpage traffic | 3,000 | Sign up | Sign up | Sign up |
| Employee Rating | 58 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | 38 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 7,392 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,367 | Sign up | Sign up | Sign up |
| Twitter Mentions | 6 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 38 | Sign up | Sign up | Sign up |
| Linkedin Employees | 55 | Sign up | Sign up | Sign up |
About RedHill Biopharma
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases.
| Price | $6.40 |
| Target Price | Sign up |
| Volume | 8,100 |
| Market Cap | $8M |
| Year Range | $6.21 - $19 |
| Dividend Yield | 0% |
| PE Ratio | 0.09 |
| Analyst Rating | 0% buy |
| Industry | Drug Manufacturers |
In the news
 |
RedHill Biopharma (NASDAQ:RDHL) Now Covered by StockNews.comDecember 31 - ETF Daily News |
 |
RedHill Biopharma awarded judgement of approx $8M by NY Supreme CourtDecember 2 - Yahoo |
 |
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme CourtDecember 1 - Yahoo |
RedHill Biopharma to Present Opaganib at U.S. Defense ConferenceOctober 27 - TipRanks |
|
 |
RedHill Biopharma and Duke Collaborate on Opaganib DevelopmentOctober 22 - Yahoo |
RedHill Biopharma signs research pact with Duke University School of MedicineOctober 21 - TipRanks |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '23 | 0 | 0 | 0 | 0 | 0 | -0.200 |
| Q2 '23 | 1.8M | 810,000 | 990,000 | 760,000 | 2.7M | 0.255 |
| Q1 '23 | 13M | 8.6M | 4.2M | 2.5M | 760,000 | -1.596 |
| Q4 '22 | 13M | 8.6M | 4.2M | 2.5M | -290,000 | -0.200 |
| Q3 '22 | 18M | 9.5M | 8.1M | -64M | -1.8M | -0.200 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$144.02 0.4% | 39 |
 |
Eli Lilly and CompanyLLY |
$778.07 0.8% | 54 |
 |
PfizerPFE |
$26.61 0.3% | 46 |
 |
AstrazenecaAZN |
$65.88 0.5% | 44 |
 |
AbbVieABBV |
$179.44 1% | 47 |
Read more about RedHill Biopharma (RDHL) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of RedHill Biopharma?
The Market Cap of RedHill Biopharma is $8M.
What is RedHill Biopharma's PE Ratio?
As of today, RedHill Biopharma's PE (Price to Earnings) ratio is 0.09.
What is the current stock price of RedHill Biopharma?
Currently, the price of one share of RedHill Biopharma stock is $6.40.
How can I analyze the RDHL stock price chart for investment decisions?
The RDHL stock price chart above provides a comprehensive visual representation of RedHill Biopharma's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling RedHill Biopharma shares. Our platform offers an up-to-date RDHL stock price chart, along with technical data analysis and alternative data insights.
Does RDHL offer dividends to its shareholders?
As of our latest update, RedHill Biopharma (RDHL) does not offer dividends to its shareholders. Investors interested in RedHill Biopharma should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of RedHill Biopharma?
Some of the similar stocks of RedHill Biopharma are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.